Demand comes among antitrust agency’s recent denial of Amgen’s Horizon buyout.
The Federal Trade Commission (FTC) has asked for more information on Pfizer’s proposed $43 billion takeover of Seagan, a biotechnology company. The request, which comes after the agency’s shutdown of Amgen’s attempt to purchase Horizon Therapeutics for $27.8 billion, has made investors skittish at the potential outcome.
Despite the request, Seagan continues to expect its merger with Pfizer will be completed in late 2023 or early 2024.
Reference: US FTC Seeks Additional Info on Pfizer's Proposed Takeover of Seagen. Reuters. July 14, 2023. Accessed July 17, 2023. https://www.reuters.com/markets/deals/us-ftc-seeks-additional-info-pfizers-proposed-takeover-seagen-2023-07-14/
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.